Hematology · NeutropeniaRegulatory Approvalregulatorymid-term

FDA Accepts BLA761147 for PEGFILGRASTIM-PCCG by Accord Biopharma

Importance8/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 8/4/2026, 6:32:46 PM

Assessment confidence: 55% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's acceptance of BLA761147 for PEGFILGRASTIM by Accord Biopharma is a significant regulatory milestone that could reshape the competitive landscape in the neutropenia treatment market. Portfolio teams must evaluate potential impacts on existing therapies and strategize accordingly. Regulatory context from FDA (FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients) supports the near-term read. Assessment grounded in 20 ranked evidence items (4 high-relevance).

Strategic Assessment

Portfolio teams should assess the competitive landscape for PEGFILGRASTIM products and consider strategic positioning against established players. The strongest clinical anchor is Evaluation, Treatment and Monitoring of Patients With Known or Suspected Parasitic Infection (ClinicalTrials.gov), moderate corpus alignment. In Hematology · Neutropenia, 6 regulatory and 4 competitive items passed relevance filtering for Accord Biopharma.

Competitive Pressure

The most relevant competitive pressure comes from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment (Humanexa Signals) — sponsor/company relevance (roche). FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need. This acceptance may position Accord Biopharma to compete in the market for neutropenia treatments, potentially impacting existing therapies.

Regulatory Outlook

Regulatory risk is concentrated around FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients (FDA). Moderate corpus alignment. The acceptance of the BLA indicates a step towards potential approval, which could influence compliance and labeling strategies for other players in the market.

Key Risks

Elevated medium regulatory exposure for Accord Biopharma could delay market entry or constrain labeling if agency review intensifies.
Signal severity is high — leadership review is warranted.

Key Opportunities

The introduction of a new PEGFILGRASTIM product could affect market share for existing therapies, potentially leading to price competition and shifts in revenue streams.
Upside for Accord Biopharma may improve if Evaluation of the Safety and Effectiveness of the CORUS™ Posterior Cervical Stabilization System 3D (PCSS 3D) for the Treatment of 2-level Cervical Degenerative Disease (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the competitive landscape for PEGFILGRASTIM products and consider strategic positioning against established players.

What Would Change This Assessment

This becomes more urgent if Monitor the progress of the review process and any upcoming announcements regarding approval timelines.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Science & Research
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Global Generic Drug Affairs
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — CAMCEVI ETM (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — ROSUVASTATIN CALCIUM (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Advancing Generic Drug Development: Leveraging Model-Integrated Evidence (MIE) in the Development & Approval of Generic Drugs - 08/27/2026
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Evaluation, Treatment and Monitoring of Patients With Known or Suspected Parasitic Infection
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Virtual Reality (VR) -Directed Brain Gut Behavioral Treatment (BGBT) for Inflammatory Bowel Disease (IBD) Inpatients
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Randomized, Controlled, Exploratory Study on the Treatment of Dental Implants Using the AmbiJet System for Peri-implantitis and Peri-implant Mucositis
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Evaluation of the Safety and Effectiveness of the CORUS™ Posterior Cervical Stabilization System 3D (PCSS 3D) for the Treatment of 2-level Cervical Degenerative Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)

Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Microneedle-based injection of Fungizone/Amphotericin B: an effective treatment for American cutaneous leishmaniasis in mice.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
The effects of sexual counseling based on the EX-PLISSIT and BETTER models on female sexual function after assisted reproductive treatment failure: a randomized clinical trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Investigation of the pharmacodynamic material basis and mechanism of Gexia Zhuyu Decoction in the treatment of primary dysmenorrhea with qi stagnation and blood stasis based on Chinmedomics.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Elucidating the therapeutic mechanism of Gomisin G from Guomin Gecoction for psoriasis treatment through targeting the PI3K-AKT/JAK3-STAT3 pathway.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy and safety of a novel 532-nm picosecond Nd:YAG laser for the treatment of freckles in Chinese patients: a randomized, split-face, multicenter, noninferiority trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Accord Biopharma
PEGFILGRASTIM
neutropenia treatment market

Commercial impact

medium

The introduction of a new PEGFILGRASTIM product could affect market share for existing therapies, potentially leading to price competition and shifts in revenue streams.

Regulatory impact

medium

The acceptance of the BLA indicates a step towards potential approval, which could influence compliance and labeling strategies for other players in the market.

What to watch

Monitor the progress of the review process and any upcoming announcements regarding approval timelines.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.